MONEY

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Read More

Tags:

Previous Article

The Declaration of Independence and current threats to liberal democracy

Next Article

Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivone...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Germany's Commerzbank has a bumpy history with big M&A

Germany's Commerzbank has a bumpy history with big M&A

Tomas Kauer - Mode... Sep 12, 2024

Zeta Global stock soars to all-time high of $27.39

Zeta Global stock soars to all-time high of $27.39

Tomas Kauer - Mode... Sep 14, 2024

FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

FDA Approves Genentech's Tecentriq Hybreza, the First a...

Tomas Kauer - Mode... Sep 13, 2024